tauopathies

Summary

Summary: Neurodegenerative disorders involving deposition of abnormal tau protein isoforms (TAU PROTEINS) in neurons and glial cells in the brain. Pathological aggregations of tau proteins are associated with mutation of the tau gene on chromosome 17 in patients with ALZHEIMER DISEASE; DEMENTIA; PARKINSONIAN DISORDERS; progressive supranuclear palsy (SUPRANUCLEAR PALSY, PROGRESSIVE); and corticobasal degeneration.

Top Publications

  1. ncbi Tau-mediated neurodegeneration in Alzheimer's disease and related disorders
    Carlo Ballatore
    Center for Neurodegenerative Disease Research, Department of Pathology and Laboratory Medicine, University of Pennsylvania, 3600 Spruce Street, Philadelphia, Pennsylvania 19104 4283, USA
    Nat Rev Neurosci 8:663-72. 2007
  2. ncbi Chronic lithium treatment decreases tau lesions by promoting ubiquitination in a mouse model of tauopathies
    Hanae Nakashima
    Department of Neuropsychiatry, Okayama University Graduate School of Medicine and Dentistry, 700-8558, Okayama, Japan
    Acta Neuropathol (Berl) 110:547-56. 2005
  3. ncbi Transgenic Drosophila models of Alzheimer's disease and tauopathies
    Kanae Iijima-Ando
    Laboratory of Neurogenetics and Pathobiology, Department of Biochemistry and Molecular Biology, Farber Institute for Neurosciences, Thomas Jefferson University, 900 Walnut Street, JHN410, Philadelphia, PA, 19107, USA
    Brain Struct Funct 214:245-62. 2010
  4. ncbi Tau pathology in Alzheimer disease and other tauopathies
    Khalid Iqbal
    Department of Neurochemistry, New York State Institute for Basic Research in Developmental Disabilities, 1050 Forest Hill Road, Staten Island, NY 10314 6399, USA
    Biochim Biophys Acta 1739:198-210. 2005
  5. ncbi Tau in Alzheimer disease and related tauopathies
    K Iqbal
    Department of Neurochemistry, New York State Institute for Basic Research in Developmental Disabilities, 1050 Forest Hill Road, Staten Island, New York 10314 6399, USA
    Curr Alzheimer Res 7:656-64. 2010
  6. ncbi Tau and tauopathies
    M Robert
    Department of Neurology, Medical College, Trivandrum, Kerala, India
    Neurol India 55:11-6. 2007
  7. ncbi Tauopathies
    F Hernandez
    Centro de Biologia Molecular Severo Ochoa, CSIC UAM, Fac Ciencias, Universidad Autonoma de Madrid, Cantoblanco, 28049 Madrid, Spain
    Cell Mol Life Sci 64:2219-33. 2007
  8. ncbi Kinesin-1 transport reductions enhance human tau hyperphosphorylation, aggregation and neurodegeneration in animal models of tauopathies
    Tomas L Falzone
    Department of Cellular and Molecular Medicine, Howard Hughes Medical Institute, University of California San Diego, 9500 Gilman Drive, La Jolla, CA 92093, USA
    Hum Mol Genet 19:4399-408. 2010
  9. ncbi Tauopathies with parkinsonism: clinical spectrum, neuropathologic basis, biological markers, and treatment options
    A C Ludolph
    Department of Neurology, University of Ulm, Ulm, Germany
    Eur J Neurol 16:297-309. 2009
  10. ncbi The MAPT H1c risk haplotype is associated with increased expression of tau and especially of 4 repeat containing transcripts
    Amanda J Myers
    Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, 35 Convent Drive, Bethesda, MD 20892 3707, USA
    Neurobiol Dis 25:561-70. 2007

Research Grants

  1. In vivo imaging agents targeting Tau aggregates
    HANK KUNG; Fiscal Year: 2007
  2. CLINICAL CORRELATES OF LONGITUDINAL PET CHANGES IN AD
    Mony J de Leon; Fiscal Year: 2010
  3. CLINICAL CORRELATES OF LONGITUDINAL PET CHANGES IN AD
    Mony de Leon; Fiscal Year: 2009
  4. Canonical Wnt Signaling by the Proteolytc Processing of LRP6
    Brandon Beagle; Fiscal Year: 2007
  5. Four Repeat Tauopathy Neuroimaging Initiative
    Adam L Boxer; Fiscal Year: 2010
  6. Subgroups of Alzheimer Disease
    Khalid Iqbal; Fiscal Year: 2007
  7. PTEN, Cell Cycle and Neurofibrillary Degeneration
    Francesca Fang Liao; Fiscal Year: 2010
  8. Modeling Human Tauopathies in Drosophila melanogaster
    Gena Heidary; Fiscal Year: 2003
  9. Molecular determinants of lamin a accumulation in human aging and disease
    Agnieszka Kalinowski; Fiscal Year: 2009
  10. MECHANISM AND CONTROL OF BRAIN MICROTUBULE DYNAMICS
    Leslie Wilson; Fiscal Year: 2007

Detail Information

Publications239 found, 100 shown here

  1. ncbi Tau-mediated neurodegeneration in Alzheimer's disease and related disorders
    Carlo Ballatore
    Center for Neurodegenerative Disease Research, Department of Pathology and Laboratory Medicine, University of Pennsylvania, 3600 Spruce Street, Philadelphia, Pennsylvania 19104 4283, USA
    Nat Rev Neurosci 8:663-72. 2007
    ..our understanding of the mechanisms of tau-mediated neurodegeneration in Alzheimer's disease (AD) and related tauopathies, which are characterized by prominent CNS accumulations of fibrillar tau inclusions, are rapidly moving this ..
  2. ncbi Chronic lithium treatment decreases tau lesions by promoting ubiquitination in a mouse model of tauopathies
    Hanae Nakashima
    Department of Neuropsychiatry, Okayama University Graduate School of Medicine and Dentistry, 700-8558, Okayama, Japan
    Acta Neuropathol (Berl) 110:547-56. 2005
    ..Thus, lithium could have therapeutic benefit in neurodegenerative tauopathies by reducing tau hyperphosphorylation...
  3. ncbi Transgenic Drosophila models of Alzheimer's disease and tauopathies
    Kanae Iijima-Ando
    Laboratory of Neurogenetics and Pathobiology, Department of Biochemistry and Molecular Biology, Farber Institute for Neurosciences, Thomas Jefferson University, 900 Walnut Street, JHN410, Philadelphia, PA, 19107, USA
    Brain Struct Funct 214:245-62. 2010
    ..dementia with Parkinsonism linked to chromosome 17 (FTDP-17) and other related diseases, so called tauopathies. Although most cases are sporadic, genes associated with familial AD and FTDP-17 have been identified, which ..
  4. ncbi Tau pathology in Alzheimer disease and other tauopathies
    Khalid Iqbal
    Department of Neurochemistry, New York State Institute for Basic Research in Developmental Disabilities, 1050 Forest Hill Road, Staten Island, NY 10314 6399, USA
    Biochim Biophys Acta 1739:198-210. 2005
    ..It is this pathology which is characteristic of Alzheimer disease (AD) and other tauopathies. To date, the most established and the most compelling cause of dysfunctional tau in AD and other tauopathies ..
  5. ncbi Tau in Alzheimer disease and related tauopathies
    K Iqbal
    Department of Neurochemistry, New York State Institute for Basic Research in Developmental Disabilities, 1050 Forest Hill Road, Staten Island, New York 10314 6399, USA
    Curr Alzheimer Res 7:656-64. 2010
    ..Inhibition of abnormal hyperphosphorylation of tau offers a promising therapeutic target for AD and related tauopathies.
  6. ncbi Tau and tauopathies
    M Robert
    Department of Neurology, Medical College, Trivandrum, Kerala, India
    Neurol India 55:11-6. 2007
    ..neuronal, oligodendroglial or astrocytic filamentous tau inclusions are now grouped under the common rubric of tauopathies. The discovery of mutations in the tau gene, located on Chromosome 17 and its relationship to frontotemporal ..
  7. ncbi Tauopathies
    F Hernandez
    Centro de Biologia Molecular Severo Ochoa, CSIC UAM, Fac Ciencias, Universidad Autonoma de Madrid, Cantoblanco, 28049 Madrid, Spain
    Cell Mol Life Sci 64:2219-33. 2007
    ..of its isoforms could provoke pathological effects resulting in the appearance of neuronal disorders known as tauopathies. The purpose of this work is to review the possible mechanisms for tau alterations that could lead to the onset ..
  8. ncbi Kinesin-1 transport reductions enhance human tau hyperphosphorylation, aggregation and neurodegeneration in animal models of tauopathies
    Tomas L Falzone
    Department of Cellular and Molecular Medicine, Howard Hughes Medical Institute, University of California San Diego, 9500 Gilman Drive, La Jolla, CA 92093, USA
    Hum Mol Genet 19:4399-408. 2010
    ..hyperphosphorylation and aggregation of the microtubule-associated protein tau defines neurodegenerative tauopathies. Destabilization of microtubules by loss of tau function and filament formation by toxic gain of function are ..
  9. ncbi Tauopathies with parkinsonism: clinical spectrum, neuropathologic basis, biological markers, and treatment options
    A C Ludolph
    Department of Neurology, University of Ulm, Ulm, Germany
    Eur J Neurol 16:297-309. 2009
    b>Tauopathies with parkinsonism represent a spectrum of disease entities unified by the pathologic accumulation of hyperphosphorylated tau protein fragments within the central nervous system...
  10. ncbi The MAPT H1c risk haplotype is associated with increased expression of tau and especially of 4 repeat containing transcripts
    Amanda J Myers
    Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, 35 Convent Drive, Bethesda, MD 20892 3707, USA
    Neurobiol Dis 25:561-70. 2007
    ..We discuss these findings both in terms of the problems facing the dissection of the etiologies of complex traits and the pathogenesis of the tauopathies.
  11. ncbi Biochemistry and molecular biology of tauopathies
    Masato Hasegawa
    Department of Molecular Neurobiology, Tokyo Institute of Psychiatry, Tokyo Metropolitan Organization for Medical Research, Tokyo, Japan
    Neuropathology 26:484-90. 2006
    Filamentous tau deposits in neurons or glial cells are the hallmark lesions of neurodegenerative tauopathies, such as Alzheimer's disease, Pick's disease, corticobasal degeneration and progressive supranuclear palsy...
  12. ncbi Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathies
    Kurt R Brunden
    Center for Neurodegenerative Disease Research, Institute on Aging, Department of Pathology and Laboratory Medicine, School of Medicine, University of Pennsylvania, 3600 Spruce Street, Philadelphia, PA 19104 4283, USA
    Nat Rev Drug Discov 8:783-93. 2009
    ..of the microtubule-associated protein tau are found in numerous neurodegenerative diseases, commonly known as tauopathies. In Alzheimer's disease - the most prevalent tauopathy - misfolded tau is probably a key pathological agent...
  13. ncbi Drosophila models of human tauopathies indicate that Tau protein toxicity in vivo is mediated by soluble cytosolic phosphorylated forms of the protein
    Sébastien Feuillette
    INSERM U614, Rouen Institute for Medical Research, Faculty of Medicine, University of Rouen, Rouen Cedex, France
    J Neurochem 113:895-903. 2010
    Tau is a neuronal microtubule-associated protein involved in microtubules assembly and stabilization. Tauopathies, including Alzheimer's disease and fronto-temporal dementia with parkinsonism linked to chromosome 17, are a group of ..
  14. ncbi Effects of alpha-tocopherol on an animal model of tauopathies
    Hanae Nakashima
    Department of Neuropsychiatry, Okayama University Graduate School of Medicine and Dentistry, Shikata-cho, 700-8558, Japan
    Free Radic Biol Med 37:176-86. 2004
    ..We overexpressed the smallest human tau isoform (T44) in the mouse CNS to model tauopathies. These tau Tg mice acquire age-dependent CNS pathologies, including insoluble, hyperphosphorylated tau and ..
  15. ncbi Tauopathies: recent insights into old diseases
    Andre Delacourte
    Inserm Unit 815, 1, Place de Verdun, 59045 Lille Cedex France
    Folia Neuropathol 43:244-57. 2005
    ..Together, these observations have generated the concept of tauopathies. Indeed, each tauopathy is defined by a combination of clinical, neuropathological, biochemical and genetic ..
  16. ncbi Knock-out and transgenic mouse models of tauopathies
    Franziska Denk
    The Wellcome Trust Centre for Human Genetics, University of Oxford, Roosevelt Drive, Oxford OX3 7BN, United Kingdom
    Neurobiol Aging 30:1-13. 2009
    b>Tauopathies, characterized by the dysfunction and aggregation of the microtubule-associated protein tau (MAPT), represent some of the most devastating neurodegenerative disorders afflicting the elderly, including Alzheimer's disease and ..
  17. ncbi Neuroprotective properties of valproate: potential benefit for AD and tauopathies
    Rebekah Loy
    Department of Neurology, Program in Neurobehavioral Therapeutics, University of Rochester School of Medicine and Dentistry, Rochester, NY 14620, USA
    J Mol Neurosci 19:303-7. 2002
    ..Together, these studies will provide important tests of the hypothesis that valproate, either through inhibition of tau phosphorylation or some other mechanism, is a useful therapeutic agent to modify disease progression in AD...
  18. ncbi Concomitant TAR-DNA-binding protein 43 pathology is present in Alzheimer disease and corticobasal degeneration but not in other tauopathies
    Kunihiro Uryu
    Center for Neurodegenerative Disease Research, Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA
    J Neuropathol Exp Neurol 67:555-64. 2008
    ..These findings provide further insight into the burden and clinical significance of TDP-43 pathology in disorders other than FTLD-U and amyotrophic lateral sclerosis...
  19. ncbi A comparison of the neuronal dysfunction caused by Drosophila tau and human tau in a Drosophila model of tauopathies
    Kiren K Ubhi
    Department of Neuroscience, University of Southampton, School of Biological Sciences, Bassett Crescent East, Southampton, SO16 7PX, UK
    Invert Neurosci 7:165-71. 2007
    ..and aggregation of tau into tangles is a feature of disorders such as Alzheimer's disease and other Tauopathies. To model these disorders in Drosophila melanogaster, human tau has been over-expressed and a variety of ..
  20. ncbi O-GlcNAc modification and the tauopathies: insights from chemical biology
    Scott A Yuzwa
    Department of Molecular Biology and Biochemistry, Simon Fraser University, 8888 University Dr, Burnaby, BC, V5A 1S6, Canada
    Curr Alzheimer Res 6:451-4. 2009
    ..of the microtubule-associated protein tau into paired-helical filaments is the defining characteristic of the tauopathies. It has become apparent that the hyperphosphorylation of tau likely plays a role in the aggregation process and ..
  21. ncbi Development of a grape seed polyphenolic extract with anti-oligomeric activity as a novel treatment in progressive supranuclear palsy and other tauopathies
    Giulio Maria Pasinetti
    Center of Excellence for Novel Approaches to Neurodiagnostics and Neurotherapeutics, Brain Institute, Department of Neurology, Mount Sinai School of Medicine, New York, New York 10029 6574, USA
    J Neurochem 114:1557-68. 2010
    ..palsy (PSP), corticobasal degeneration and Alzheimer's disease among others, collectively referred to as tauopathies - are characterized by progressive, age-dependent intracellular formations of misfolded protein aggregates that ..
  22. ncbi Lipopolysaccharide-induced inflammation exacerbates tau pathology by a cyclin-dependent kinase 5-mediated pathway in a transgenic model of Alzheimer's disease
    Masashi Kitazawa
    Department of Neurobiology and Behavior, University of California Irvine, California 92697 4545, USA
    J Neurosci 25:8843-53. 2005
    ..Therefore, this study clearly demonstrates that microglial activation exacerbates key neuropathological features such as tangle formation...
  23. ncbi Tau phosphorylation and aggregation as a therapeutic target in tauopathies
    Nahuai Badiola
    Servicio de Neurologia, Hospital de Sant Pau, Universidad Autonoma de Barcelona, Barcelona, Spain
    CNS Neurol Disord Drug Targets 9:727-40. 2010
    b>Tauopathies are neurodegenerative diseases characterized by insoluble hyperphosphorylated deposits of the microtubule-associated protein tau in the central nervous system...
  24. ncbi The characterization of microtubule-stabilizing drugs as possible therapeutic agents for Alzheimer's disease and related tauopathies
    Kurt R Brunden
    Center for Neurodegenerative Disease Research and Institute on Aging, Department of Pathology and Laboratory Medicine, School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, United States
    Pharmacol Res 63:341-51. 2011
    ..Several neurodegenerative disorders referred to as tauopathies, including Alzheimer's disease and certain types of frontotemporal lobar degeneration, are characterized by the ..
  25. ncbi Alternative splicing of exon 10 in the tau gene as a target for treatment of tauopathies
    Jianhua Zhou
    Department of Medicine, Program in Neuroscience, University of Massachusetts Medical School, 364 Plantation Street, Worcester, MA 01605, USA
    BMC Neurosci 9:S10. 2008
    Tau aggregation is one of the major features in Alzheimer's disease and in several other tauopathies, including frontotemporal dementia with Parkinsonism linked to chromosome 17 (FTDP-17), and progressive supranuclear palsy (PSP)...
  26. ncbi Transgenic animal models of tauopathies
    Virginia M Y Lee
    University of Pennsylvania School of Medicine, Pathology, 3600 Spruce Street, HUP, 3rd Floor Maloney Building 1914104 4283, Philadelphia, PA, USA
    Biochim Biophys Acta 1739:251-9. 2005
    b>Tauopathies are a group of neurodegenerative disorders that include Alzheimer's disease, frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP-17) and other related diseases with prominent tau pathology...
  27. ncbi The power and richness of modelling tauopathies in Drosophila
    Katerina Papanikolopoulou
    Institute of Cellular and Developmental Biology, Biomedical Sciences Research Centre Alexander Fleming, Vari 16672, Greece
    Mol Neurobiol 44:122-33. 2011
    b>Tauopathies are a group of neurodegenerative disorders characterised by altered levels of phosphorylation or mutations in the neuronal microtubule protein Tau...
  28. ncbi Tau-positive fine granules in the cerebral white matter: a novel finding among the tauopathies exclusive to parkinsonism-dementia complex of Guam
    Mineo Yamazaki
    Department of Neuropathology, Tokyo Metropolitan Institute for Neuroscience, Fuchu shi, Tokyo, Japan
    J Neuropathol Exp Neurol 64:839-46. 2005
    ..The TFGs were hyperphosphorylated tau-positive structures that may be formed by a different mechanism from that used to produce cortical NFTs...
  29. ncbi The role of tau phosphorylation and cleavage in neuronal cell death
    Wanjoo Chun
    Department of Psychiatry, School of Medicine, University of Alabama at Birmingham, 1061 Sparks Center, 1720 7th Avenue South, Birmingham, AL 35294 0017, USA
    Front Biosci 12:733-56. 2007
    ..deposits found in Alzheimer's disease (AD) brain and also in a family of neurodegenerative diseases called 'tauopathies', where tau pathology is the primary, defining characteristic with little or no amyloid-beta (Abeta) pathology...
  30. ncbi Posttranslational modifications of tau--role in human tauopathies and modeling in transgenic animals
    Feng Chen
    Division of Psychiatry Research, , August Forel Str. 1, , Switzerland
    Curr Drug Targets 5:503-15. 2004
    ..of scant or no beta-amyloid plaques characterizes additional neurodegenerative disorders collectively called tauopathies. In the course of plaque and NFT formation, the major proteinaceous components of these lesions undergo post-..
  31. ncbi The role of tau (MAPT) in frontotemporal dementia and related tauopathies
    R Rademakers
    Department of Molecular Genetics, Neurogenetics Group, Flanders Interuniversity Institute for Biotechnology, University of Antwerp, Antwerpen, Belgium
    Hum Mutat 24:277-95. 2004
    ..In addition, the role of tau as a genetic susceptibility factor is discussed, together with the genetic evidence for additional causal genes for tau-positive as well as tau-negative dementia...
  32. ncbi A minimal length between tau exon 10 and 11 is required for correct splicing of exon 10
    Qingming Yu
    Department of Medicine and Program in Neuroscience, University of Massachusetts Medical School, Worcester, Massachusetts, USA
    J Neurochem 90:164-72. 2004
    ..tau mRNA cause frontotemporal dementia with parkinsonism, associated with chromosome 17 (FTDP-17), and other tauopathies. This suggests that the ratio of exon 10 inclusion to exclusion in adult brain is one of the factors to ..
  33. ncbi Tau nitration occurs at tyrosine 29 in the fibrillar lesions of Alzheimer's disease and other tauopathies
    Matthew R Reynolds
    Department of Cell and Molecular Biology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois 60611, USA
    J Neurosci 26:10636-45. 2006
    The neurodegenerative tauopathies are a clinically diverse group of diseases typified by the pathological self-assembly of the microtubule-associated tau protein...
  34. ncbi Pathological tau: a loss of normal function or a gain in toxicity?
    John Q Trojanowski
    Nat Neurosci 8:1136-7. 2005
  35. ncbi Cell-cycle markers in a transgenic mouse model of human tauopathy: increased levels of cyclin-dependent kinase inhibitors p21Cip1 and p27Kip1
    Patrice Delobel
    Medical Research Council Laboratory of Molecular Biology, Hills Road, Cambridge CB2 2QH, UK
    Am J Pathol 168:878-87. 2006
    ..and cause the hyperphosphorylation and filament formation of tau protein in Alzheimer's disease and other tauopathies. Here we have analyzed the expression and/or activation of proteins involved in cell-cycle progression in the ..
  36. ncbi Metabolic/signal transduction hypothesis of Alzheimer's disease and other tauopathies
    Khalid Iqbal
    Department of Neurochemistry, New York State Institute for Basic Research in Developmental Disabilities, Staten Island, 10314 6399, USA
    Acta Neuropathol 109:25-31. 2005
    ..However, the molecular mechanisms of neither AD nor other tauopathies are completely understood...
  37. ncbi Argyrophilic grain disease: a late-onset dementia with distinctive features among tauopathies
    Markus Tolnay
    Institute of Pathology, Department of Neuropathology, University Hospital Basel, Basel, Switzerland
    Neuropathology 24:269-83. 2004
    ....
  38. ncbi Tau alteration and neuronal degeneration in tauopathies: mechanisms and models
    Roland Brandt
    Department of Neurobiology, University of Osnabruck, Barbarastrasse 11, D 49076 Osnabrück, Germany
    Biochim Biophys Acta 1739:331-54. 2005
    ..altered both functionally and structurally in several neurodegenerative diseases now collectively called tauopathies. Although increasing evidence supports that alterations of tau may directly cause neuronal degeneration and ..
  39. ncbi Pinning down phosphorylated tau and tauopathies
    Jormay Lim
    Cancer Biology Program Division of Hematology Oncology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Avenue, NRB 1030K, Boston, MA 02215, USA
    Biochim Biophys Acta 1739:311-22. 2005
    ..Thus, Pin1 is pivotal in maintaining normal neuronal function and preventing age-dependent neurodegeneration. This could represent a promising interventive target to prevent neurodegenerative diseases...
  40. ncbi Quantitative analysis of tau isoform transcripts in sporadic tauopathies
    J W Connell
    Department of Neuroscience, Institute of Psychiatry, King s College London, De Crespigny Park, London SE5 8AF, UK
    Brain Res Mol Brain Res 137:104-9. 2005
    ..Therefore, dysregulation of tau pre-mRNA splicing may be a contributing factor to sporadic tauopathies. To address this question, we devised a real-time RT-PCR strategy based on the use of a single fluorogenic ..
  41. ncbi Mutations causing neurodegenerative tauopathies
    Michel Goedert
    MRC Laboratory of Molecular Biology, Hills Road, Cambridge CB2 2QH, UK
    Biochim Biophys Acta 1739:240-50. 2005
    ..of experimental animal models that reproduce the essential molecular and cellular features of the human tauopathies, including the formation of abundant filaments made of hyperphosphorylated tau protein and nerve cell ..
  42. ncbi Clinicopathological features of the tauopathies
    B Murray
    Department of Neurology, Mater Misericordiae University Hospital, Eccles Street, Dublin 7, Ireland
    Biochem Soc Trans 33:595-9. 2005
    ..clinicopathological diversity of the tau-related disorders with specific reference to three of the most common tauopathies, frontotemporal dementia (familial and sporadic), progressive supranuclear palsy and corticobasal degeneration.
  43. ncbi Cellular tau pathology and immunohistochemical study of tau isoforms in sporadic tauopathies
    Mari Yoshida
    Department of Neuropathology, Institute for Medical Science of Aging, Aichi Medical University, Aichi, Japan
    Neuropathology 26:457-70. 2006
    ..fibrillary aggregates of abnormally hyperphosphorylated tau protein are characteristic features in sporadic tauopathies. In the first part of this paper we outline the morphological features of some major sporadic tauopathies...
  44. ncbi Study of tauopathies by comparing Drosophila and human tau in Drosophila
    Xinping Chen
    State Key Laboratory of Brain and Cognitive Science, Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101, China
    Cell Tissue Res 329:169-78. 2007
    ..Here, we have investigated the potential mechanisms underlying tauopathies by comparing Drosophila (d-tau) and human (h-tau) tau in a Drosophila model...
  45. ncbi RNA and protein-dependent mechanisms in tauopathies: consequences for therapeutic strategies
    J M Gallo
    MRC Centre for Neurodegeneration Research, King s College London, Institute of Psychiatry, Box P037, De Crespigny Park, London, SE5 8AF, UK
    Cell Mol Life Sci 64:1701-14. 2007
    b>Tauopathies are a group of neurodegenerative diseases characterised by intracellular deposits of the microtubule-associated protein tau. The most typical example of a tauopathy is Alzheimer's disease...
  46. ncbi Apolipoprotein E epsilon 4 is a determinant for Alzheimer-type pathologic features in tauopathies, synucleinopathies, and frontotemporal degeneration
    Keith A Josephs
    Department of Neurology, Mayo Clinic, Rochester, MN 55905, USA
    Arch Neurol 61:1579-84. 2004
    To determine if apolipoprotein E epsilon 4 influences the frequency of Alzheimer-type pathologic features in tauopathies, synucleinopathies, and frontotemporal degeneration and to determine if the frequency of Alzheimer-type pathologic ..
  47. ncbi Comparison of family histories in FTLD subtypes and related tauopathies
    J S Goldman
    Memory and Aging Center, University of California, San Francisco, CA 94117, USA
    Neurology 65:1817-9. 2005
    ..FTD/ALS was the most and SD the least heritable subtype. FTLD syndromes appear to have different etiologies and recurrence risks...
  48. ncbi Proteasome subunit proteins and neuropathology in tauopathies and synucleinopathies: Consequences for proteomic analyses
    Mohamed Zouambia
    Faculte des Sciences Biologiques, Université des Sciences et des Technologies Houari Boumediène, Algiers, Algeria
    Proteomics 8:1221-36. 2008
    ..In other tauopathies (Pick's disease, frontotemporal dementia, progressive supranuclear palsy and argyrophilic grain disease), ..
  49. ncbi Leucine-rich repeat kinase 2 colocalizes with alpha-synuclein in Parkinson's disease, but not tau-containing deposits in tauopathies
    George Perry
    Department of Pathology, Case Western Reserve University, Cleveland, Ohio, USA
    Neurodegener Dis 5:222-4. 2008
    ..Mutations in leucine-rich repeat kinase 2 (LRRK2) are thus far the most frequent genetic cause associated with autosomal dominant and idiopathic Parkinson's disease...
  50. ncbi Microglial activation in brain lesions with tau deposits: comparison of human tauopathies and tau transgenic mice TgTauP301L
    Atsushi Sasaki
    Department of Human Pathology, Gunma University Graduate School of Medicine, Gunma, Japan
    Brain Res 1214:159-68. 2008
    ..to phosphorylated tau accumulation and the characteristics of microglial activation in brain lesions of human tauopathies in comparison to mutant tau transgenic (TG) mice...
  51. ncbi Anti-tau phospho-specific Ser262 antibody recognizes a variety of abnormal hyper-phosphorylated tau deposits in tauopathies including Pick bodies and argyrophilic grains
    I Ferrer
    Institut de Neuropatologia, Servei d Anatomia Patològica, Hospital Princeps d Espanya, Spain
    Acta Neuropathol 104:658-64. 2002
    ..in astrocytes suggests different kinase equipment and activation in comparing neurons and astrocytes in tauopathies. Pick bodies in PiD and grains in AGD are weakly, or not all, immunostained in tissue samples with long post-..
  52. ncbi Identification of non-Alzheimer's disease tauopathies-related proteins by proteomic analysis
    Guofeng Yang
    Department of Geriatric Neurology, Chinese PLA General Hospital, Beijing 100853, China
    Neurol Res 30:613-22. 2008
    To identify differentially expressed proteins between tauopathies cases and controls and to explore molecular mechanisms of tauopathies.
  53. ncbi NeuroScale, the battery of behavioral tests with novel scoring system for phenotyping of transgenic rat model of tauopathy
    Miroslava Korenova
    Institute of Neuroimmunology, Slovak Academy of Sciences, AD Centre, Dubravska cesta 9, 84510 Bratislava, Slovakia
    J Neurosci Methods 177:108-14. 2009
    ....
  54. ncbi Rat tau proteome consists of six tau isoforms: implication for animal models of human tauopathies
    Jozef Hanes
    Axon Neuroscience GmbH, Rennweg, Vienna, Austria
    J Neurochem 108:1167-76. 2009
    ..containing either three (3R) or four (4R) repeat domains, all of which participate in the pathogenesis of human tauopathies. To investigate the role of tau protein in the disease, transgenic rat models have been created...
  55. ncbi Human misfolded truncated tau protein promotes activation of microglia and leukocyte infiltration in the transgenic rat model of tauopathy
    Norbert Zilka
    Institute of Neuroimmunology, Slovak Academy of Sciences, Bratislava, Slovak Republic
    J Neuroimmunol 209:16-25. 2009
    It has been hypothesized that misfolded tau protein could be a mediator of the inflammatory response in human tauopathies. Here we show that neurodegenerative lesions caused by human truncated tau promote inflammatory response manifested ..
  56. ncbi Repression of tau hyperphosphorylation by chronic endurance exercise in aged transgenic mouse model of tauopathies
    Yea Hyun Leem
    Department of Chemistry and Nano Science, and Brain Disease Research Institute, Ewha Womans University, Seoul, Korea
    J Neurosci Res 87:2561-70. 2009
    ..To address this, the transgenic (Tg) mouse model of tauopathies, Tg-NSE/htau23, which expresses human tau23 in the brain, was chosen...
  57. ncbi Analysis of tauopathies with transgenic mice
    M Hutton
    Department of Neuroscience, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL, USA
    Trends Mol Med 7:467-70. 2001
    ..protein tau are a feature of several neurodegenerative diseases (including Alzheimer's disease) known as tauopathies. A pivotal finding was the identification in 1998 of mutations in tau associated with frontotemporal dementia ..
  58. ncbi Retarded axonal transport of R406W mutant tau in transgenic mice with a neurodegenerative tauopathy
    Bin Zhang
    The Center for Neurodegenerative Disease Research, Department of Pathology and Laboratory Medicine, and Institute on Aging, The University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104 4283, USA
    J Neurosci 24:4657-67. 2004
    ..of filamentous tau inclusions are neuropathological hallmarks of neurodegenerative diseases known as tauopathies. The discovery of multiple pathogenic tau gene mutations in many kindreds with familial frontotemporal dementia ..
  59. ncbi Roles of heat-shock protein 90 in maintaining and facilitating the neurodegenerative phenotype in tauopathies
    Wenjie Luo
    Laboratory of Molecular and Cellular Neuroscience, The Rockefeller University and Fisher Foundation for Alzheimer s Disease, New York, NY 10021, USA
    Proc Natl Acad Sci U S A 104:9511-6. 2007
    ..b>Tauopathies are neurodegenerative diseases characterized by aberrant phosphorylation and/or expression of Tau protein, ..
  60. ncbi Pathological properties of the Parkinson's disease-associated protein DJ-1 in alpha-synucleinopathies and tauopathies: relevance for multiple system atrophy and Pick's disease
    Manuela Neumann
    Institute of Neuropathology, Ludwig Maximilians University of Munich, Munich, Germany
    Acta Neuropathol (Berl) 107:489-96. 2004
    ..antibodies against DJ-1, we have performed a comprehensive investigation of DJ-1 in alpha-synucleinopathies and tauopathies. DJ-1 was abundantly expressed in reactive astrocytes of patients with neurodegenerative diseases...
  61. ncbi Nitration of tau protein is linked to neurodegeneration in tauopathies
    Takashi Horiguchi
    Department of Pathology and Laboratory Medicine, Center for Neurodegenerative Disease Research, Institute on Aging, University of Pennsylvania School of Medicine, Philadelphia, PA 19104 4283, USA
    Am J Pathol 163:1021-31. 2003
    ..revealed that tau-positive filaments in tangle-bearing neurons were also labeled by n847 and IHC of other tauopathies showed that some of glial and neuronal tau pathologies in CBD, progressive supranuclear palsy, PiD, and ..
  62. ncbi Pin1 colocalization with phosphorylated tau in Alzheimer's disease and other tauopathies
    Pankajavalli Ramakrishnan
    F 526, Department of Pathology, Albert Einstein College of Medicine, Bronx, NY 10461, USA
    Neurobiol Dis 14:251-64. 2003
    ..Pin1 granules were sparse in PSP, and rarely did A-20 colocalize with TG-3. The appearance of Pin1 granules in the early stages of AD, PiD, and FTDP-17 (P301L) implicates Pin1 in their pathogenesis but not in PSP...
  63. ncbi Abnormal Sp1 transcription factor expression in Alzheimer disease and tauopathies
    G Santpere
    Institut Neuropatologia, Servei Anatomia Patològica, IDIBELL Hospital Universitari de Bellvitge, carrer Feixa Larga sn, 08907 Hospitalet de Llobregat, Spain
    Neurosci Lett 397:30-4. 2006
    ..involved in amyloid and tau, and Sp1 is regulated by oxidative stress, the present findings suggest that Sp1 deposition in hyper-phosphorylated tau deposits may have functional consequences in the pathology of AD and other tauopathies.
  64. ncbi Truncated tau expression levels determine life span of a rat model of tauopathy without causing neuronal loss or correlating with terminal neurofibrillary tangle load
    Peter Koson
    Institute of Neuroimmunology, Slovak Academy of Sciences, AD Centre, Dubravska cesta 9, 845 10 Bratislava, Slovak Republic
    Eur J Neurosci 28:239-46. 2008
    ..These findings suggest that the expression levels of misfolded truncated tau determine the life span in a transgenic rat model of tauopathy without causing neuronal loss or correlating with terminal NFT load...
  65. ncbi Similar brain tau pathology in DM2/PROMM and DM1/Steinert disease
    C A Maurage
    INSERM U422, Faculte de Medecine, Lille, France
    Neurology 65:1636-8. 2005
    ..A reduced expression of tau exon 2 and exon 3 epitopes is observed in both DM1 and DM2. This suggests a similar physiopathologic process that may contribute to common neurologic features in patients with DM...
  66. ncbi From progressive nonfluent aphasia to corticobasal syndrome: a case report of corticobasal degeneration
    R Sanchez-Valle
    UCSF Memory and Aging Center, San Francisco, California 94143 1207, USA
    Neurocase 12:355-9. 2006
    ..This case demonstrates the clinical overlap between frontotemporal lobar degeneration and CBD. In this case, early motor speech impairment predicted earlier and more accurately than CBS the presence of underlying tau-pathology and CBD...
  67. ncbi Inducible expression of Tau repeat domain in cell models of tauopathy: aggregation is toxic to cells but can be reversed by inhibitor drugs
    Inna Khlistunova
    Max Planck Unit for Structural Molecular Biology, DESY, Hamburg, Germany
    J Biol Chem 281:1205-14. 2006
    ....
  68. ncbi The pathogenesis of Alzheimer's disease and the role of Abeta42
    Todd E Golde
    CNS Spectr 12:4-6. 2007
  69. ncbi Neurodegeneration and Alzheimer's disease: the lesson from tauopathies
    G Sorrentino
    University of Naples Parthenope, via Acton 38, I 80133 Naples, Italy
    Neurol Sci 28:63-71. 2007
    ..Collectively, these observations suggest a model of AD whereby overproduction or reduced clearance of Abeta initiates a cascade of events that lead to neuronal loss directly or through post-translational modification of tau...
  70. ncbi A mouse model to study tau pathology related with tau phosphorylation and assembly
    Tobias Engel
    Centro de Biologia Molecular Severo Ochoa, CSIC UAM, 28049 Madrid, Spain
    J Neurol Sci 257:250-4. 2007
    ..In that model we have suggested a possible role for tau phosphorylation, but not for tau aggregation, in the cognitive impairment found in the transgenic mouse...
  71. ncbi Neurogenesis and cell cycle-reactivated neuronal death during pathogenic tau aggregation
    K Schindowski
    INSERM, U837, Place de Verdun, Lille Cedex, France
    Genes Brain Behav 7:92-100. 2008
    ..Altogether, these data suggest that cell cycle events in THY-Tau22 are resulting from neurogenesis in young animals and cell death in older ones. It suggests that neuronal cell death in such models is much more complex than believed...
  72. ncbi Tangle diseases and the tau haplotypes
    John Hardy
    Laboratory of Neurogenetics, National Institutes on Aging and of Neurological Diseases and Stroke, National Institutes of Health, Bethesda, MD 20852, USA
    Alzheimer Dis Assoc Disord 20:60-2. 2006
    ..We discuss the reason for this disequilibrium, its evolutionary history, and the role of genetic variability at MAPT in the etiology of tauopathies.
  73. ncbi Kinase activities increase during the development of tauopathy in htau mice
    Ian Kelleher
    King s College London, Department of Neuroscience, MRC Centre for Neurodegeneration Research, Institute of Psychiatry, De Crespigny Park, London, UK
    J Neurochem 103:2256-67. 2007
    ..These data suggest that cdk5 and p38 may be associated with pathological changes in wild-type human tau during the progressive development of tauopathy...
  74. ncbi Ultrastructural characteristics of tau filaments in tauopathies: immuno-electron microscopic demonstration of tau filaments in tauopathies
    Kunimasa Arima
    Department of Laboratory Medicine, Musashi Hospital, National Center of Neurology and Psychiatry, 4 1 1, Ogawahigashi, Kodaira, Tokyo 187 8551, Japan
    Neuropathology 26:475-83. 2006
    ..In sporadic tauopathies, individual tau filaments show characteristic sizes, shapes and arrangements, and therefore contribute to ..
  75. ncbi The potential for beta-structure in the repeat domain of tau protein determines aggregation, synaptic decay, neuronal loss, and coassembly with endogenous Tau in inducible mouse models of tauopathy
    Maria Magdalena Mocanu
    Max Planck Unit for Structural Molecular Biology, 22607 Hamburg, Germany
    J Neurosci 28:737-48. 2008
    ..5 months. However, tangles of mouse Tau, hyperphosphorylation, and missorting remain, suggesting an extended lifetime of aggregated wild-type Tau once a pathological conformation and aggregation is induced by a proaggregation Tau species...
  76. ncbi Split GFP complementation assay: a novel approach to quantitatively measure aggregation of tau in situ: effects of GSK3beta activation and caspase 3 cleavage
    Wanjoo Chun
    Department of Psychiatry, University of Alabama at Birmingham School of Medicine, Alabama, USA
    J Neurochem 103:2529-39. 2007
    ..These data demonstrate that split GFP complementation may be a valuable approach to determine the aggregation process in living cells...
  77. ncbi A neuronal microtubule-interacting agent, NAPVSIPQ, reduces tau pathology and enhances cognitive function in a mouse model of Alzheimer's disease
    Yasuji Matsuoka
    Department of Neurology, Georgetown University Medical Center, 4000 Reservoir Road N W, Washington, DC 20057, USA
    J Pharmacol Exp Ther 325:146-53. 2008
    ..abnormal conformation represent one of the major pathological hallmarks of Alzheimer's disease (AD) and other tauopathies. However, recent data suggest that the pathogenic processes leading to cognitive impairment occur before the ..
  78. ncbi Pathological inclusion bodies in tauopathies contain distinct complements of tau with three or four microtubule-binding repeat domains as demonstrated by new specific monoclonal antibodies
    R De Silva
    Reta Lila Weston Institute of Neurological Studies, University College London, and Department of Molecular Neuroscience and Neuropathology, Institute of Neurology, UK
    Neuropathol Appl Neurobiol 29:288-302. 2003
    ..containing fibrillar aggregates of hyperphosphorylated tau protein are a characteristic feature in the tauopathies, which include Alzheimer's disease, frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP-17),..
  79. ncbi Early axonopathy preceding neurofibrillary tangles in mutant tau transgenic mice
    Karelle Leroy
    Laboratory of Histology and Neuropathology, Universite Libre de Bruxelles, School of Medicine, 808, Route de Lennik, Bldg G, 1070 Brussels, Belgium
    Am J Pathol 171:976-92. 2007
    ..This Tg30tau model thus provides evidence that axonopathy precedes tangle formation and that both lesions can be dissociated from overt neuronal loss in selected brain areas but not from neuronal dysfunction...
  80. ncbi A novel calcium-binding protein is associated with tau proteins in tauopathy
    Irving E Vega
    Department of Biology, University of Puerto Rico Rio Piedras Campus, San Juan, Puerto Rico
    J Neurochem 106:96-106. 2008
    b>Tauopathies are a group of neurological disorders characterized by the presence of intraneuronal hyperphosphorylated and filamentous tau. Mutations in the tau gene have been found in kindred with tauopathy...
  81. ncbi A novel transgenic mouse expressing double mutant tau driven by its natural promoter exhibits tauopathy characteristics
    Hanna Rosenmann
    The Department of Neurology, The Agnes Ginges Center for Human Neurogenetics, Hadassah University Medical Center, Jerusalem, Israel
    Exp Neurol 212:71-84. 2008
    The neurofibrillary-tangles (NTFs), characteristic of tauopathies including Alzheimer's-disease (AD), are the pathological features which correlate best with dementia...
  82. ncbi TAp73alpha induces tau phosphorylation in HEK293a cells via a transcription-dependent mechanism
    Claudie Hooper
    King s College London, MRC Centre for Neurodegenerative Research, Institute of Psychiatry, De Crespigny Park, Denmark Hill, London SE5 8AF, UK
    Neurosci Lett 401:30-4. 2006
    ..These findings have ramifications for microtubule dynamics associated with axonal growth during development and for neuronal death associated with Alzheimer's disease and other tauopathies.
  83. ncbi Cognitive and motor assessment in autopsy-proven corticobasal degeneration
    R Murray
    Department of Neurology, University of Pennsylvania School of Medicine, Philadelphia, PA 19104 4283, USA
    Neurology 68:1274-83. 2007
    ..To investigate the clinical features of autopsy-proven corticobasal degeneration (CBD)...
  84. ncbi Ultrastructural neuronal pathology in transgenic mice expressing mutant (P301L) human tau
    Wen-Lang Lin
    Mayo Clinic, Jacksonville, Florida 32224, USA
    J Neurocytol 32:1091-105. 2003
    ..The other type resembled ballooned neurons seen in some human tauopathies. The nucleus was peripherally placed, but normal appearing...
  85. ncbi Prospect of therapeutic approaches to tauopathies
    Hanno M Roder
    NADAG, Landsberger Strasse 50, 80339 Munich, Germany
    J Mol Neurosci 20:195-202. 2003
    ..The latter is found exclusively inside cells. Aggregated tau in all tauopathies including AD is abnormally modified by the excess incorporation of chemical groups called phosphates (..
  86. ncbi 4-repeat tauopathy sharing pathological and biochemical features of corticobasal degeneration and progressive supranuclear palsy
    Omi Katsuse
    Department of Psychiatry, Yokohama City University School of Medicine, 3 9 Fukuura, Kanazawa Ku, 236 0004 Yokohama, Japan
    Acta Neuropathol 106:251-60. 2003
    ..The present case shared tau-related pathological and biochemical features of CBD and PSP. These findings support that CBD and PSP are closely associated disorders having a pathogenesis common to 4R tauopathy...
  87. ncbi Co-localization of glycogen synthase kinase-3 with neurofibrillary tangles and granulovacuolar degeneration in transgenic mice
    Takashi Ishizawa
    Department of Neuroscience, Mayo Clinic Jacksonville, Jacksonville, FL 32225, USA
    Am J Pathol 163:1057-67. 2003
    ....
  88. ncbi Primary progressive aphasia as the initial manifestation of corticobasal degeneration and unusual tauopathies
    I Ferrer
    Banc de Teixits Neurològics, Universitat de Barcelona Hospital Clinic, Barcelona, Spain
    Acta Neuropathol 106:419-35. 2003
    ..Taken together, the present series further supports pure and combined CBD as causes of primary progressive aphasia, and they extend the hypothesis that primary progressive aphasia may be the initial symptom of distinct tauopathies.
  89. ncbi Dementia with Lewy bodies from the perspective of tauopathy
    Eizo Iseki
    Department of Psychiatry, Yokohama City University School of Medicine, 3 9 Fukuura, Kanazawa Ku, Japan
    Acta Neuropathol 105:265-70. 2003
    ....
  90. ncbi Anatamopathological spectrum of tauopathies
    Tamas Revesz
    Queen Square Brain Bank, Department of Molecular Neuroscience, Institute of Neurology, University College London, London, United Kingdom
    Mov Disord 18:S13-20. 2003
    ..a major neuropathological feature in a significant group of neurodegenerative diseases, which are described as tauopathies. In one category of such diseases, the neuronal inclusions occur in association with extracellular deposition ..
  91. ncbi Chronic lithium treatment decreases mutant tau protein aggregation in a transgenic mouse model
    Mar Perez
    Centro de Biologia Molecular Severo Ochoa, CSIC UAM Facultad de Ciencias, Universidad Autonoma de Madrid, Madrid 28049, Spain
    J Alzheimers Dis 5:301-8. 2003
    ..into neurofibrillary tangles are characteristic features of several neurodegenerative disorders referred to as tauopathies. Among them, frontotemporal dementia and Parkinsonism linked to chromosome 17 may be caused by dominant ..
  92. ncbi Rapid neurofibrillary tangle formation after localized gene transfer of mutated tau
    Ronald L Klein
    Department of Pharmacology and Therapeutics, Louisiana State University Health Sciences Center, Shreveport, Louisiana 71130, USA
    Am J Pathol 164:347-53. 2004
    ..The ability to produce neurofibrillary pathology in adult rodents makes this a useful method to study tau-related neurodegeneration...
  93. ncbi Soluble amyloid beta-protein is increased in frontotemporal dementia with tau gene mutations
    Antonella Vitali
    Department of Neurological Sciences, Psychiatry and Genetics, University of Genova, Italy
    J Alzheimers Dis 6:45-51. 2004
    ..The results demonstrate that the aggregation of tau protein produces an accumulation of Abeta, which, however, does not reach the critical concentration needed for Abetaplaques formation...
  94. ncbi Tau protein and neurodegeneration
    Michel Goedert
    Medical Research Council Laboratory of Molecular Biology, Hills Road, Cambridge CB2 2QH, UK
    Semin Cell Dev Biol 15:45-9. 2004
    ..At an experimental level, the new understanding is leading to the development of good transgenic animal models of the tauopathies.
  95. ncbi Non-Alzheimer's disease dementias: anatomic, clinical, and molecular correlates
    Craig E Hou
    Department of Neurology, University of California at San Francisco, USA
    Can J Psychiatry 49:164-71. 2004
    ..We also discuss the pharmacologic treatment of these disorders...
  96. ncbi Phosphorylated p38MAPK specific antibodies cross-react with sarkosyl-insoluble hyperphosphorylated tau proteins
    Naruhiko Sahara
    Department of Neuroscience, Mayo Clinic, Jacksonville, Florida, USA
    J Neurochem 90:829-38. 2004
    ..Together, the results indicate that the cross-reactivity of antiactive-p38MAPK antibody with phosphorylated tau is responsible for the immunolabeling of tau-positive inclusion...
  97. ncbi [Structure and role of the tau protein]
    Marta Baksalerska-Pazera
    , Instytut Nenckiego PAN w Warszawie, ul. Pasteura 3, 02-093 Warszawa
    Postepy Biochem 48:287-95. 2002
  98. ncbi Cholesterol storage and tau pathology in Niemann-Pick type C disease in the brain
    Roland Distl
    Institut fur Anatomie, Charite, Humboldt Universitat, Berlin, Germany
    J Pathol 200:104-11. 2003
    ....
  99. ncbi Tau-predominant-associated pathology in a sporadic late-onset Hallervorden-Spatz syndrome
    Juan J Zarranz
    Neurology Service, Hospital de Cruces, Department of Neurosciences, University of the Basque Country, Baracaldo, Vizcaya, Spain
    Mov Disord 21:107-11. 2006
    ....
  100. ncbi [The microtubule-associated protein tau in neurodegenerative diseases. Tauopathies]
    M P Sanchez
    Centro de Biologia Molecular, C S I C Universidad de Madrid, Cantoblanco, 28049, Espana
    Rev Neurol 33:169-77. 2001
    ..Those pathologies presenting a tau disfunction are known as tauopathies.
  101. ncbi BetaII-tubulin and phospho-tau aggregates in Alzheimer's disease and Pick's disease
    B Puig
    , IDIBELL-Hospital Universitario de Bellvitge, Spain
    J Alzheimers Dis 7:213-20; discussion 255-62. 2005
    ..Taken together, these findings support the view that high betaII-tubulin content is a contributing factor in the formation of abnormal hyper-phosphorylated tau aggregates...

Research Grants85

  1. In vivo imaging agents targeting Tau aggregates
    HANK KUNG; Fiscal Year: 2007
    ..Alzheimer's disease and other Tauopathies are neurodegenerative diseases of the brain...
  2. CLINICAL CORRELATES OF LONGITUDINAL PET CHANGES IN AD
    Mony J de Leon; Fiscal Year: 2010
    ..This project will test the hypothesis that validated biological markers for neurofibrillary tangle and amyloid plaque pathology contribute to FDG-PET in predicting future cognitive decline in cognitively normal subjects. ..
  3. CLINICAL CORRELATES OF LONGITUDINAL PET CHANGES IN AD
    Mony de Leon; Fiscal Year: 2009
    ..This project will test the hypothesis that validated biological markers for neurofibrillary tangle and amyloid plaque pathology contribute to FDG-PET in predicting future cognitive decline in cognitively normal subjects. ..
  4. Canonical Wnt Signaling by the Proteolytc Processing of LRP6
    Brandon Beagle; Fiscal Year: 2007
    ..and has been implicated in generating aberrantly hyperphosporylated tau proteins associated with AD and other tauopathies. Hence, identifying the mechanisms and proteins that regulate GSK3 activity will provide pertinent pathological ..
  5. Four Repeat Tauopathy Neuroimaging Initiative
    Adam L Boxer; Fiscal Year: 2010
    ..Increasingly, clinical trials of such tau therapies are focusing on pure tauopathies, or disorders in which tau is causally- or strongly-linked to the underlying pathology in the absence of other ..
  6. Subgroups of Alzheimer Disease
    Khalid Iqbal; Fiscal Year: 2007
    ..tau, a hallmark brain lesion of Alzheimer disease (AD), Down syndrome, frontotemporal dementia, and other tauopathies, and employ this information to identify and diagnose the different subgroups of Alzheimer's disease...
  7. PTEN, Cell Cycle and Neurofibrillary Degeneration
    Francesca Fang Liao; Fiscal Year: 2010
    ..Although NFTs are coincident with cell death in several neurodegenerative diseases, known as tauopathies, and most notably in AD, the molecular mechanisms leading to this chronic loss of neuronal cells is still not ..
  8. Modeling Human Tauopathies in Drosophila melanogaster
    Gena Heidary; Fiscal Year: 2003
    ..melanogaster to determine the role of the microtubule-associated protein (MAP) tau in the pathogenesis of human tauopathies. The tau protein has been implicated in at least 20 neurodegenerative diseases collectively referred to as ..
  9. Molecular determinants of lamin a accumulation in human aging and disease
    Agnieszka Kalinowski; Fiscal Year: 2009
    ..other pathologies that result from destructive protein-membrane interactions, such as Alzheimer's disease, tauopathies and prion diseases...
  10. MECHANISM AND CONTROL OF BRAIN MICROTUBULE DYNAMICS
    Leslie Wilson; Fiscal Year: 2007
    ..how the tau proteins, which stabilize microtubules and may mis-regulate dynamics in neurodegenerative tauopathies such as Frontotemporal Dementia with Parkinsonism linked to chromosome 17 (FTDP-17) and the stathmin/SCG10 ..
  11. MECHANISM AND CONTROL OF BRAIN MICROTUBULE DYNAMICS
    Leslie Wilson; Fiscal Year: 2009
    ..how the tau proteins, which stabilize microtubules and may mis-regulate dynamics in neurodegenerative tauopathies such as Frontotemporal Dementia with Parkinsonism linked to chromosome 17 (FTDP-17) and the stathmin/SCG10 ..
  12. A conditional model of Neurofibrillary Pathology
    Jada Lewis; Fiscal Year: 2003
    ..The tau neuropathology in these mice is strikingly similar to the neurofibrillary tangles observed in human tauopathies. Although our tau model makes it possible to study the earliest stages of neurodegeneration associated with tau ..
  13. Abnormal Hyperphosphorylation of Tau
    Khalid Iqbal; Fiscal Year: 2007
    ..on this knowledge, identify specific therapeutic targets for Alzheimer disease (AD), Down syndrome and other tauopathies which are characterized by this brain lesion...
  14. A kinase pathway required for cortical neuron polarization
    Franck Polleux; Fiscal Year: 2010
    ..Recent evidence suggested that LKB1 disruption could participate to tauopathies such as Alzheimer's disease...
  15. In Search of the Molecular Basis of Memory Loss in Tauopathy
    Karen H Ashe; Fiscal Year: 2010
    ....
  16. Role of PP2A in tauopathies
    Estelle Sontag; Fiscal Year: 2006
    ..the hypothesis that their disruption promotes the accumulation of hyperphosphorylated forms of tau in all tauopathies. The first aim will focus on establishing major properties of PP2A/tau and PP2A/MT interactions in vitro and in ..
  17. Role of PP2A in tauopathies
    Estelle Sontag; Fiscal Year: 2007
    ..PP2A in human brain regions during normal aging, and assess whether it becomes altered in AD and other tauopathies. If our model is validated, dietary folate supplementation and PPMT may be novel therapeutic targets for ..
  18. Hsp90 inhibitors as suppressors of protein misfolding toxicity
    Gabriela Chiosis; Fiscal Year: 2007
    ..formation leading to aberrant Tau phosphorylation, and that of mutant but not WT Tau protein are maintained in tauopathies by Hsp90...
  19. Suppression of Tauopathy by Lysosomal Activation
    Jason Eriksen; Fiscal Year: 2007
    ..This observation suggests that in Alzheimer's disease and other tauopathies the presence of tangles (a pathological hallmark of these diseases) may be due to the impaired clearance of ..
  20. Biology of Tauopathies Studied with HSV Amplicons
    E Antonio Chiocca; Fiscal Year: 2007
    ....
  21. The Molecular Structure and Function of Tau Protein
    Stuart Feinstein; Fiscal Year: 2007
    ..the conclusion that pathological tau action is likely a key component in Alzheimer's, FTDP-17 and additional "tauopathies"...
  22. Genetic Analysis of Tau H1 in Parkinsonism
    Matthew Farrer; Fiscal Year: 2006
    The tau H1 association in 4R tauopathies, including progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD), is fundamental to their etiology, yet the underlying mutation(s) and functional effects on tau biology remain ..
  23. Role of the Prolyl lsomerase Pin1 in Alzheimer's Disease
    Kun Ping Lu; Fiscal Year: 2007
    ..In this proposal, we will continue to investigate how this enzyme affects the disease processes and hope to eventually identify new therapeutic targets. ..
  24. Role of the Prolyl lsomerase Pin1 in Alzheimer's Disease
    Kun Ping Lu; Fiscal Year: 2010
    ..In this proposal, we will continue to investigate how this enzyme affects the disease processes and hope to eventually identify new therapeutic targets. ..
  25. Genetic and Environmental Risk Factors for PSP
    Irene Litvan; Fiscal Year: 2009
    ..Understanding the etiology of PSP may also help explain the causes of other tauopathies such as Alzheimer's disease...
  26. Genetic and Environmental Risk Factors for PSP
    Irene Litvan; Fiscal Year: 2007
    ..Understanding the etiology of PSP may also help explain the causes of other tauopathies such as Alzheimer's disease...
  27. Neurofibrillary Tangle-Induced Dementia in AD
    Travis Dunckley; Fiscal Year: 2007
    ..without concomitant amyloid pathology in a broad class of neurodegenerative diseases, collectively known as "tauopathies." This suggests that NFTs themselves are intricately involved in neurodegenerative processes...